Clinical trialHuman
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018. Gusev EI, Martynov MY, Kostenko EV and 2 others.
Study type
Clinical trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published
2018
PubMed
Where PepCue cites this
This paper is part of the evidence base behind these profiles. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Adrenocorticotropic HormoneAgedBrain IschemiaBrain-Derived Neurotrophic FactorFemaleHumansMaleMiddle AgedPeptide FragmentsStrokeStroke Rehabilitation
Other papers on N-Acetyl Semax Amidate
Journal article · 2021
[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain]
Journal article · 2011[The effect of semax and its C-end peptide PGP on expression of the neurotrophins and their receptors in the rat brain during incomplete global ischemia]
Journal article · 2006Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page